TranspireBio

Our Leadership Team

    HOME > Our Company > Our Member > Abhishek Gupta, Ph.D., PMP
Abhishek Gupta, Ph.D., PMP
Chief Scientific Officer
Chief Corporate Development Officer (interim)

Abhishek Gupta, Ph.D., PMP, ‘Abhi’, is Transpire Bio’s Chief Scientific Officer (CSO) and interim Chief Corporate Development Officer. Dr. Gupta is responsible for the scientific direction of Transpire Bio. As a member of the leadership team, Abhishek Gupta Ph.D., PMP is responsible for providing the strategic and operational leadership to develop and implement the company’s scientific strategy, overall product portfolio and conceptualization and introduction of new product opportunities. Dr. Gupta is also responsible for establishing and executing Transpire Bio’s corporate development strategy including evaluation of new product opportunities and M&A to expand existing business and create new business.

Dr. Gupta is a seasoned and accomplished bio-pharmaceutical executive with over 23 years of product development experience across dosage forms with over 20 years focused primarily on inhalation drug-device combination products. Dr. Gupta’s time in industry has included leadership positions at Novartis Pharmaceuticals, Nektar Therapeutics, Cardinal Health, Lupin, and his most recent position at Cipla as the SVP & Head of R&D, North America. Dr. Gupta has successfully led the product development and approval of several branded and generic dosage forms including small molecules, polypeptides, proteins and biologics for registration in the US and EU.

Dr. Gupta is a graduate of Harvard Business Schools’ business analytics program. Dr. Gupta has a Ph.D. in Pharmaceutical Sciences from the University of Arizona, US with a focus on Pharmaceutics, Analytical and Material Sciences. He is a certified project management professional (PMP) through the Project Management Institute (PMI) of America and has a Bachelors in Pharmacy (B. Pharm.) from India. Dr. Gupta has over 50 peer reviewed publications and numerous granted and filed patents.